Carbonic anhydrase

Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS

Retrieved on: 
Wednesday, November 29, 2023
Research, TLX, Carbonic anhydrase, Breast cancer, IIT, Patient, Triple-negative breast cancer, Congress, ASX, CAIX, Diagnosis, PET, ICO, TNBC, Medical imaging

MELBOURNE, Australia, Nov. 29, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with triple-negative breast cancer (TNBC), will be presented at the 2023 San Antonio Breast Cancer Symposium® (SABCS) taking place from December 5-9, 2023.

Key Points: 
  • MELBOURNE, Australia, Nov. 29, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with triple-negative breast cancer (TNBC), will be presented at the 2023 San Antonio Breast Cancer Symposium® (SABCS) taking place from December 5-9, 2023.
  • Dr. Caroline Rousseau, Principal Investigator for the OPALESCENCE study (ClinicalTrials.gov ID NCT04758780 ) at the Institut de Cancérologie de l'Ouest (ICO) in St Herblain (France), will deliver top-line results as a poster presentation at 5pm CT on Wednesday December 6.
  • SABCS is the largest and most prestigious scientific gathering on breast cancer research worldwide.
  • Visit http://www.sabcs.org/ for more information on the congress.

Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS

Retrieved on: 
Wednesday, November 29, 2023
Research, TLX, Carbonic anhydrase, Breast cancer, IIT, Patient, Triple-negative breast cancer, Congress, ASX, CAIX, Diagnosis, PET, ICO, TNBC, Medical imaging

MELBOURNE, Australia, Nov. 29, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with triple-negative breast cancer (TNBC), will be presented at the 2023 San Antonio Breast Cancer Symposium® (SABCS) taking place from December 5-9, 2023.

Key Points: 
  • MELBOURNE, Australia, Nov. 29, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with triple-negative breast cancer (TNBC), will be presented at the 2023 San Antonio Breast Cancer Symposium® (SABCS) taking place from December 5-9, 2023.
  • Dr. Caroline Rousseau, Principal Investigator for the OPALESCENCE study (ClinicalTrials.gov ID NCT04758780 ) at the Institut de Cancérologie de l'Ouest (ICO) in St Herblain (France), will deliver top-line results as a poster presentation at 5pm CT on Wednesday December 6.
  • SABCS is the largest and most prestigious scientific gathering on breast cancer research worldwide.
  • Visit http://www.sabcs.org/ for more information on the congress.

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology

Retrieved on: 
Tuesday, March 28, 2023
Tissue, Antigen, Intellectual property, DNA, Chemical library, Renal cell carcinoma, Dels, Ligand, Research, HIT, Blood, Protein, CAIX, Machine learning, DEL, Carbonic anhydrase, Drug discovery, Artificial intelligence, Neoplasm, Hypoxia, DNA-encoded chemical library, Vaccine, Pharmaceutical industry, Jaden Philogene

Siena, Italy, March 28, 2023 - Philogen S.p.A., a clinical-stage biotechnology company focused on the development of innovative antibody and small molecule ligands, announces the publication of a new study conducted in collaboration with Google focused on the use of Machine Learning models applied to the screening of DNA-Encoded Chemical Libraries (DELs).

Key Points: 
  • Siena, Italy, March 28, 2023 - Philogen S.p.A., a clinical-stage biotechnology company focused on the development of innovative antibody and small molecule ligands, announces the publication of a new study conducted in collaboration with Google focused on the use of Machine Learning models applied to the screening of DNA-Encoded Chemical Libraries (DELs).
  • The technology allows the rapid selection of specific binders (“Phenotype”), physically connected to unique DNA tags (“Genotype”) that work as amplifiable identification barcodes.
  • Philochem has synthesized several DNA-Encoded Chemical Libraries, featuring different designs, that have yielded high affinity and selective binders to a variety of target proteins of pharmaceutical interest.
  • These ligands - human monoclonal antibodies or small organic molecules - are identified using Antibody Phage Display Libraries and DNA-Encoded Chemical Library technologies.

Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market

Retrieved on: 
Monday, October 17, 2022
LinkedIn, Congress, Australian Securities Exchange, Head, ICI, Lactic acid, Neoplasm, GE Healthcare, Thomas Edison, TGA, Association, Advertising, Cancer, Carbonic anhydrase, NYSE, Regulation of tobacco by the U.S. Food and Drug Administration, HIV disease progression rates, Company, Marketing, Industry, Nuclear medicine, Diversified Pharmaceutical Services, European Association for the Study of the Liver, Disclosure, FDA, Risk, Review, EANM, Research, Multimedia, Immunotherapy, Degenerative disease, Gallium, Veni, vidi, vici, PD-1, Ecosystem, Oxygen, View, ASX, Patient, European Association of Nuclear Medicine, Partnership, Food, TLX, United Kingdom, PET, Forward-looking statement, JAMA Network Open, Medical imaging, Pharmaceutical industry, Animal, Media, Telix

TLX250-CDx and [18F]-FLac complement GE Healthcare Pharmaceutical Diagnostics' pipeline of investigational non-invasive [18F]-CD8 and[18F]-Granzyme-B imaging tracers for use by pharmaceutical companies in clinical trials, with the potential to predict and monitor response to immunotherapy.

Key Points: 
  • TLX250-CDx and [18F]-FLac complement GE Healthcare Pharmaceutical Diagnostics' pipeline of investigational non-invasive [18F]-CD8 and[18F]-Granzyme-B imaging tracers for use by pharmaceutical companies in clinical trials, with the potential to predict and monitor response to immunotherapy.
  • Sanka Thiru, Global Business Leader, Immuno-Oncology, at GE Healthcare's Pharmaceutical Diagnostics business, said: "This partnership expands our pharmaceutical services offering, including our toolbox of investigational PET imaging diagnostics.
  • Telix and GE Healthcare will explore validation of [18F]-FLac for use in GE Healthcare's FASTlab, an automated PET radiochemistry synthesiser, widely used for onsite production of FDG6 and other PET tracers.
  • The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates all rights reserved.

Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market

Retrieved on: 
Monday, October 17, 2022
LinkedIn, Congress, Australian Securities Exchange, Head, ICI, Lactic acid, Neoplasm, GE Healthcare, Thomas Edison, TGA, Association, Advertising, Cancer, Carbonic anhydrase, NYSE, Regulation of tobacco by the U.S. Food and Drug Administration, HIV disease progression rates, Company, Marketing, Industry, Nuclear medicine, Diversified Pharmaceutical Services, European Association for the Study of the Liver, Disclosure, FDA, Risk, Review, EANM, Research, Immunotherapy, Degenerative disease, Gallium, Veni, vidi, vici, PD-1, Ecosystem, Oxygen, ASX, Patient, European Association of Nuclear Medicine, Partnership, Food, TLX, United Kingdom, PET, Forward-looking statement, JAMA Network Open, Medical imaging, Pharmaceutical industry, Animal, Media, Telix

Sanka Thiru, Global Business Leader, Immuno-Oncology, at GE Healthcare's Pharmaceutical Diagnostics business, said: "This partnership expands our pharmaceutical services offering, including our toolbox of investigational PET imaging diagnostics.

Key Points: 
  • Sanka Thiru, Global Business Leader, Immuno-Oncology, at GE Healthcare's Pharmaceutical Diagnostics business, said: "This partnership expands our pharmaceutical services offering, including our toolbox of investigational PET imaging diagnostics.
  • Telix and GE Healthcare will explore validation of [18F]-FLac for use in GE Healthcare's FASTlab, an automated PET radiochemistry synthesiser, widely used for onsite production of FDG6 and other PET tracers.
  • The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates all rights reserved.
  • CONTACT: Telix Investor Relations: Ms. Kyahn Williamson, Telix Pharmaceuticals Limited, SVP Corporate Communications and Investor Relations, Email: [email protected] ; GE Healthcare Media Contact: Debbie Leven / [email protected] , +44 7785 456999

EANM Presentations to Showcase New Data and Developments in Telix's Theranostics Pipeline

Retrieved on: 
Monday, October 10, 2022
LinkedIn, Carbonic anhydrase, Congress, Nuclear medicine, Australian Securities Exchange, ASX, Radio, Institute, Regulation of tobacco by the U.S. Food and Drug Administration, Radboud University Medical Center, Patient, PSMA, European Association of Nuclear Medicine, EANM, Research, Cancer, Degenerative disease, Food, TGA, Gallium, Company, Department, Association, Breast cancer, TLX, Prostate cancer, Head, European Association of Urology, Department of Urology, University of Virginia, FDA, Kidney, External beam radiotherapy, Pharmaceutical industry, Medical imaging, Vaccine, Animal, Telix, Urology

Our sponsored symposium provides an insight to the advancements in imaging, surgery and patient management for the genitourinary oncology field.

Key Points: 
  • Our sponsored symposium provides an insight to the advancements in imaging, surgery and patient management for the genitourinary oncology field.
  • The breadth of our innovative theranostic pipeline is demonstrative of our commitment and progress towards advancing nuclear medicine across a range of indications."
  • EANM presentation details are as follows:
    Chairperson: Professor Wolfgang Fendler- Vice Chair, Clinic for Nuclear Medicine, EssenUniversity Hospital, Essen, Germany.
  • -Professor JochenWalz - Head of the Department of Urology at the Institut Paoli-Calmettes Cancer Centre, Marseille, France.

Monrol Is Partnering With Telix Pharmaceuticals, Supplying Lutetium nca Lu 177 for the Manufacturing of Clinical Doses for the Phase II STARLITE 2 Study At MSK and Manufacturing Clinical Doses for Telix’s Phase III ZIRCON Trial

Retrieved on: 
Tuesday, May 10, 2022
Science, Other Science, Pharmaceutical, Medical Supplies, Oncology, Health, Hospitals, Clinical Trials, TGA, Safety, Radionuclide, Nivolumab, Degenerative disease, Gallium, CDMO, Carbonic anhydrase, Positron emission tomography, Quality of life, Radiopharmaceutical, Technology, Nuclear medicine, Transport, CFR, ASX, PRRT, Phase, Australian Securities Exchange, Kidney cancer, Oncology, MRI, Patient, NET, Clinical trial, Lung, CA9, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MTR, Breakthrough therapy, LinkedIn, Prostate, Neoplasm, Title 21 CFR Part 11, Histology, Bristol Myers Squibb, PET/CT, Memorial Sloan Kettering Cancer Center, GMP, Movement, Cancer, MSK, Food, Radiation, CT, Diagnosis, Kidney, Prostate cancer, PET, Pharmaceutical industry, Vaccine, Medical imaging, Tax advisor, Animal, Telix, Lutetium

Monrol supplied Lutetium (Lu-177 n.c.a) to Telix Pharmaceuticals to manufacture clinical doses of TLX250 for STARLITE 2 Phase II study.

Key Points: 
  • Monrol supplied Lutetium (Lu-177 n.c.a) to Telix Pharmaceuticals to manufacture clinical doses of TLX250 for STARLITE 2 Phase II study.
  • Clinical doses of Telixs investigational renal cancer companion imaging agent TLX250-CDx (89Zr-DFO-girentuximab) is also produced by Eczacbas Monrol in its Istanbul facility for the Phase III ZIRCON clinical trial.
  • ZIRCON Phase III study (Zirconium Imaging in Renal Cancer Oncology) is an international multi-centre study at 34 sites in Europe, Australia, Turkey, Canada, and the United States.
  • Telixs companion investigational diagnostic imaging agent TLX250-CDx (89Zr-DFO-girentuximab) is the subject of a global Phase III trial recruiting (ZIRCON trial, NCT03849118 ).

ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment

Retrieved on: 
Monday, March 7, 2022
PET, Kidney cancer, Diagnosis, Carbonic anhydrase, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MTR, COVID, BLA, Patient, Zirconium, Special access program, Australian Securities Exchange, TGA, Food, Breakthrough therapy, Biologics license application, Emory University School of Medicine, Gallium, Clinical research, LinkedIn, CT, FDA, ASX, Clear cell renal cell carcinoma, Disease, TLX, Trial of the century, EAP, Authorization, Lung, Kidney, Department of Urology, University of Virginia, MRI, Department, GLOBE, Degenerative disease, Pharmaceutical industry, Medical imaging, Telix

MELBOURNE, Australia, March 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that ZIRCON (Zirconium in Renal Cancer Oncology, NCT03849118) a pivotal Phase III study of investigational renal (kidney) cancer imaging agent TLX250-CDx has dosed 252 patients, the target enrolment for the study.

Key Points: 
  • MELBOURNE, Australia, March 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that ZIRCON (Zirconium in Renal Cancer Oncology, NCT03849118) a pivotal Phase III study of investigational renal (kidney) cancer imaging agent TLX250-CDx has dosed 252 patients, the target enrolment for the study.
  • Dr Colin Hayward, Telixs Chief Medical Officer said, We are pleased to have reached this important milestone in our Phase III program, and to have reached target enrolment.
  • ZIRCON (Zirconium Imaging in Renal Cancer Oncology, NCT03849118) is an international multicentre Phase III study at 34 sites in Europe, Australia, Turkey, Canada and the United States.
  • ZIRCON is a prospective imaging trial in renal cancer patients undergoing kidney surgery with the objective of determining the sensitivity and specificity of TLX250-CDx PET imaging to detect clear cell renal cell cancer (ccRCC) in comparison with histologic standard of truth determined from surgical resection specimens.

Bruker Enables High-Throughput Multiplex HTS on Sierra SPR Platform

Retrieved on: 
Monday, February 7, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Bruker, Multimedia, Protein, Conference, Lightning, Automation, Research, Solution, Software, Biomedical Research, Data analysis, Proteomics, Cell biology, CH, Exhibition, SPR, Carbonic anhydrase, Sierra, Life, Novartis Institute for Tropical Diseases, HTS, Sutro Biopharma, Nasdaq, Disease, Atomic mass, Antibody, Microscopy, Fine chemical, Genedata

The innovative microfluidic system of the Bruker Sierra SPR-32 Pro provides a unique 8x4 array for parallel readout of 32 measurement sensor spots per injection at exceptional robustness.

Key Points: 
  • The innovative microfluidic system of the Bruker Sierra SPR-32 Pro provides a unique 8x4 array for parallel readout of 32 measurement sensor spots per injection at exceptional robustness.
  • View the full release here: https://www.businesswire.com/news/home/20220207005150/en/
    The Bruker Sierra SPR-32 Pro offers throughput-optimized assay set-ups for the development of both biologics and small molecule drug candidates.
  • Brukers highly sensitive SPR detection enables measurements at high molecular weight differences between analyte and target of 10-3, supporting even fragment-based drug design.
  • Moreover, Bruker has developed automated 24/7 SPR plate-handling operation, or by its automation interface for SPR integration in HTS, which works with common scheduling software from various vendors.

First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer

Retrieved on: 
Monday, December 20, 2021
Squamous cell carcinoma, TAT, TLX, GLOBE, Neck, Institute, Bladder cancer, Head, ASX, Cancer, MTR, Safety, Disease, Carbonic anhydrase, Risk, Partnership, Nuclear medicine, Industry, ICO, Company, Clear cell renal cell carcinoma, Lung, Human, Patient, CA9, Pharmaceutical industry, Medical imaging, Telix, NMIBC

(ATONCO) today announce that a first patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle-invasive bladder cancer (NMIBC) at the Institut de Cancrologie de lOuest (ICO) in St Herblain, France.

Key Points: 
  • (ATONCO) today announce that a first patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle-invasive bladder cancer (NMIBC) at the Institut de Cancrologie de lOuest (ICO) in St Herblain, France.
  • The objective of PERTINENCE1 an investigator-led, open-label, proof of concept study, is to evaluate safety, biodistribution and dosing properties of TLX250-CDx (89Zr-DFO-girentuximab) in patients with NMIBC.
  • The PERTINENCE study builds on the Telix and ATONCO licence and development agreement announced in December 2019,2 and will be led by Dr. Caroline Rousseau at ICO.
  • It will recruit 6 patients over 12 months, with a successful outcome leading to therapeutic studies with astatine-211 (211At) for targeted alpha therapy (TAT).